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after	optimal	cytoreductive	surgery.	All	procedures	were	per-Intraoperative IP chemotherapy in ovarian cancer

















































Table 1. Characteristics of patients (n=10)
Variables Values
Age (yr)*  41 (28-52)
Body mass index*   21.6 (17.3-27.3)
Comorbidity at the time of surgery   1
Neoadjuvant chemotherapy  0
CA-125 (U/mL)*  51.4 (10.0-12,860.0)
Stage  
   IC 6
   IIIB 1
   IIIC  3
Histology  
   Serous  4
   Mucinous  2
   Endometrioid  2
   Clear cell  2
Grade  
   1 5
   2  2
   3 3
*Values are presented as median (range). 




   Unilateral 5
   Bilateral 5
Pelvic lymph node dissection  10
Paraaortic lymph node dissection  9
Omentectomy  10
Appendectomy 8
Bladder peritoneum resection 1
Rectal serosa resection 1
Table 3. Surgical outcomes
Variables  Values
Duration of surgery (min)* 340 (210-420)
Intraoperative blood loss (mL)* 500 (200-2,000)
   ≤1,000  8
   >1,000  2
Transfusion  6
Length of hospital day*  16 (6-23)
Chemotherapy day after surgery*  18 (12-26)


































Table 4. Incidence of perioperative adverse events by organ system and grade
Organ system Incidence
Adverse event
Grade 1 Grade 2 Grade 3 Grade 4
Gastrointestinal (n=14) 5 9
   Nausea/vomiting  9 2 7 - -
   Ileus  2 2 - - -
   Diarrhea  1 - 1 - -
   AST/ALT elevatioin 2 1 1 - -
Hematologic (n=6) 3 3
   Anemia  6 - 3 3 -
Pulmonary (n=2) 1 1
   Pleural effusion  2 1 1 - -
Genitourinary (n=1) 1
   Hypercreatinemia  1 1 - - -
Total  23 7 (30.4%) 13 (56.5%) 3 (13.0%) -
Percentage indicates incidence of each grade among total adverse events. 
AST/ALT, aspartate aminotransferase/alanine aminotransferase.
Fig. 1. Incidence (%) of 23 grade (G) 1 to 3 adverse events in patients 
with primary epithelial ovarian cancer who underwent cytoreductive 
surgery followed by intraoperative intraperitoneal (IP) chemotherapy. 
Nine of 10 patients experienced more than one adverse event of 
which 87% were grade 1 or 2. AST/ALT, aspartate aminotransferase/
alanine aminotransferase.Intraoperative IP chemotherapy in ovarian cancer
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Standards for Different Types of Articles
Guidelines	for	six	different	types	of	articles	have	been	adopted	by	the	Journal of Gynecologic Oncology:
1. CONSORT	(Consolidated	Standards	of	Reporting	Trials)	standards	for	reporting	randomized	trials
2. PRISMA	(Preferred	Reporting	Items	for	Systematic	Reviews	and	Meta-analyses)	guidelines	for	
reporting	systematic	reviews	and	meta-analyses
3. MOOSE	(Meta-analysis	of	Observational	Studies	in	Epidemiology)	guidelines	for	meta-analyses	
and	systematic	reviews	of	observational	studies
4. STROBE	(Strengthening	the	Reporting	of	Observational	Studies	in	Epidemiology)	guidelines	for	
the	reporting	of	observational	studies
5. STARD	(Standards	for	Reporting	of	Diagnostic	Accuracy)	standards	for	reporting	studies	of	diag-
nostic	accuracy
6. REMARK	(Reporting	of	Tumor	Markers	Studies)	guidelines	for	reporting	tumor	marker	prognos-
tic	studies
		Investigators	who	are	planning,	conducting,	or	reporting	randomized	trials,	meta-analyses	of	ran-
domized	trials,	meta-analyses	of	observational	studies,	observational	studies,	studies	of	diagnostic	
accuracy,	or	tumor	marker	prognostic	studies	should	be	familiar	with	these	sets	of	standards	and	
follow	these	guidelines	in	articles	submitted	for	publication.
NOW AVAILABLE ONLINE	-	http://www.ejgo.org